about
Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimenEbolavirus vaccines for humans and apesPrime-boost immunization strategies against Chikungunya virusOncolytic Viruses: Therapeutics With an Identity CrisisDNA immunization as a technology platform for monoclonal antibody inductionAdvances in structure-based vaccine designAllergens are not pathogens: why immunization against allergy differs from vaccination against infectious diseasesPotentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protectionRecombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1Effect of vaccine administration modality on immunogenicity and efficacy.Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical TrialsDistribution of primed T cells and antigen-loaded antigen presenting cells following intranasal immunization in miceStructural allele-specific patterns adopted by epitopes in the MHC-I cleft and reconstruction of MHC:peptide complexes to cross-reactivity assessmentA two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaksOptimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.Plant-based anti-HIV-1 strategies: vaccine molecules and antiviral approaches.Evaluation of multivalent H2 influenza pandemic vaccines in mice.Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch.Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles.A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virusLactobacillus plantarum producing a Chlamydia trachomatis antigen induces a specific IgA response after mucosal booster immunization.Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.Prime-boost immunization using a DNA vaccine delivered by attenuated Salmonella enterica serovar typhimurium and a killed vaccine completely protects chickens from H5N1 highly pathogenic avian influenza virus.Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice.TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia)Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.Oral delivery of the Sj23LHD-GST antigen by Salmonella typhimurium type III secretion system protects against Schistosoma japonicum infection in mice.Vaccines and immunotherapeutics for the treatment of malignant diseaseProtective effect of a prime-boost strategy with the Ts87 vaccine against Trichinella spiralis infection in miceCross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate.The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccinationDengue vaccines: recent developments, ongoing challenges and current candidates.Archaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8 T cell responses.Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infectionA self-help program for memory CD8+ T cells: positive feedback via CD40-CD40L signaling as a critical determinant of secondary expansionSchistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum).Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruziIntravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms
P2860
Q21089693-95F174E6-3940-433D-9C38-63EC55422343Q24631696-8B7407E7-77E5-46B2-A2E9-E00535AA77EBQ24701774-D5B37A44-F714-49AD-B2CA-60D06244B451Q26741020-EDD87524-8140-4236-BF91-C16F83C33560Q26751432-9CC3B5BF-8CE1-4C26-BFCB-A7F3FD8AF376Q26824545-7E42C26B-31D7-445C-98DF-29C3612A2A81Q26828969-B73CD9DB-31B1-4FED-AFD9-6B9CCBDD8C02Q27305883-97971234-3188-4589-8649-C89F6D2528B4Q27321063-4517D684-5D25-4754-BE1E-9C2E774A3FFAQ27692376-368FC77D-AF57-4B8A-BD9D-0CF28ED0818AQ28394899-F79D805B-F896-48F0-9C95-35A08DBEE15CQ28477998-951ACE2E-FA90-42E2-AE32-93C91CA35538Q28752409-57B95011-0361-4D4B-802A-9EC4C0715213Q29048611-035B3808-4A04-4EFE-B613-059F68EB90A7Q30368929-0480C591-8FD3-440D-B345-79FC66910120Q30392083-44F09D30-BD0D-4CB7-9E51-3682A4403D1AQ30398507-B870EA7F-F28B-4180-BB89-8A8104FD06EFQ30402500-98EB5A44-8F6C-448C-873D-C93FECEDA2FEQ30415387-140EA906-0751-4FBF-9C07-FA47FA32B6B5Q30430152-6F7830FC-9A38-4F9E-9094-E5493E3F0A3DQ31037728-7CDB4638-C4A7-4E5D-A626-416769FE1F1AQ33632705-21494669-4ED0-4EC3-919C-DEBC3420D674Q33759392-B2A6C59A-B273-45DF-9852-7446777AF7AAQ33768698-C9A68DDF-CD72-4428-8E3F-122F39338E40Q33818084-21F7E52B-F687-40B0-9D31-759FC77FEBE5Q33939303-4A726BDD-6CFC-4EBB-9AA9-3206D84CC39FQ33955745-E87A31B4-4DB6-4F54-96E1-620B6CD9C71FQ34016693-FFC9EE28-C1D0-4F5A-8348-F3B414B0CB58Q34170074-9586D4A6-1198-4056-A232-3DE38C1AB8FFQ34183489-CBB7460C-11F9-446B-BCBA-104C1CDBC646Q34204047-41531426-F7B2-4FAB-9118-18D45DB7425AQ34232909-470AC5ED-C473-409C-9276-A112FF05E4ACQ34291205-4CD321D9-F114-4B5D-8EA7-044ECFFB5DBEQ34367194-D74F0DEA-6950-492E-A5B7-7F23E80964C8Q34557185-16CCFE0E-173C-4D52-9F80-613AE7C2924FQ34700649-6BCC7836-12C7-4C70-878F-618A7299BF80Q34746500-A7AE3AEC-6F95-423B-869A-BD419E33F6F8Q34899535-C7688806-E43F-4BFB-A483-AF14A32D9F9FQ34931648-A5DB2B5A-9B55-45C4-AAD4-A58E5BD63F39Q35061979-5C776405-10D9-4B8D-8E8E-CB75F05657C1
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Heterologous prime-boost vaccination.
@en
Heterologous prime-boost vaccination.
@nl
type
label
Heterologous prime-boost vaccination.
@en
Heterologous prime-boost vaccination.
@nl
prefLabel
Heterologous prime-boost vaccination.
@en
Heterologous prime-boost vaccination.
@nl
P2860
P1476
Heterologous prime-boost vaccination
@en
P2093
P2860
P304
P356
10.1016/J.COI.2009.05.016
P50
P577
2009-06-06T00:00:00Z